Mylan Pharmaceuticals Inc., the US-based subsidiary of Mylan Inc. has launched Norethindrone tablets USP, 0.35 mg. Norethindrone tablets are the generic version of Watson Laboratories' (now Actavis, Inc.) Nor-Q.D. tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of pregnancy.

Mylan's partner, Famy Care received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Norethindrone tablets USP, 0.35 mg, had US sales of approximately $39 million for the 12 months ending March 31, 2013, according to IMS Health.

Currently, Mylan has 174 ANDAs pending FDA approval representing $83.2 billion in annual sales, according to IMS Health. Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $22.9 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. The company innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.